American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 31, Issue 2 , Pages 78-83 , March 2010

Intratumoral delivery of docetaxel enhances antitumor activity of Ad-p53 in murine head and neck cancer xenograft model

  • George H. Yoo, MD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • Corresponding Author InformationCorresponding author. Department of Otolaryngology-Head and Neck Surgery, Wayne State University, 5E University Health Center, 540 East Canfield Avenue, Detroit, MI 48201, USA. Tel.: +1 313 745 4336; fax: +1 313 577 8555.
    • ,
  • Geetha Subramanian, MD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • ,
  • Waleed H. Ezzat, MD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • ,
  • Ozlem E. Tulunay, MD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • Department of Surgery, John D. Dingell VA Medical Center, Detroit, MI, USA
    • ,
  • Vivian R. Tran, MD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • ,
  • Fulvio Lonardo, MD

      Affiliations

    • Department of Pathology, Wayne State University and Karmanos Cancer Institute, Detroit, Detroit, MI, USA
    • ,
  • John F. Ensley, MD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • Department of Medicine, Division of Hematology/Oncology, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • ,
  • Harold Kim, MD

      Affiliations

    • Department of Radiation Oncology, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • ,
  • Joshua Won

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • ,
  • Timothy Stevens

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • ,
  • Louis A. Zumstein, PhD

      Affiliations

    • Introgen Therapeutics, Inc., Houston, TX, USA
    • ,
  • Ho-Sheng Lin, MD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • Department of Surgery, John D. Dingell VA Medical Center, Detroit, MI, USA

Received 18 May 2008

References 

  1. American Cancer Society. Estimated new cancer cases and deaths by sex for all sites, US, 2007. Cancer Facts Fig. 2007;4
  2. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310–1317
  3. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–98
  4. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081–2086
  5. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324:1685–1690
  6. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996;88:890–899
  7. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–1952
  8. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–1944
  9. Laramore GE, Scott CB, al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys. 1992;23:705–713
  10. Xie M, Zhou L, Hu T, et al. Intratumoral delivery of paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts. Anticancer Drugs. 2007;18:459–466
  11. Harper E, Dang W, Lapidus RG, et al. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin Cancer Res. 1999;5:4242–4248
  12. Wenig BL, Werner JA, Castro DJ, et al. The role of intratumoral therapy with cisplatin/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2002;128:880–885
  13. Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer. 2000;1:32–40[discussion 41-2]
  14. Belani CP. Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments. Semin Oncol. 1999;26:15–18
  15. Kaye SB, Vasey PA. Docetaxel in ovarian cancer: phase III perspectives and future development. Semin Oncol. 2002;29:22–27
  16. Schrijvers D, Vermorken JB. Role of taxoids in head and neck cancer. Oncologist. 2000;5:199–208
  17. Posner MR, Glisson B, Frenette G, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001;19:1096–1104
  18. Colevas AD, Busse PM, Norris CM, et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol. 1998;16:1331–1339
  19. Colevas AD, Norris CM, Tishler RB, et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol. 1999;17:3503–3511
  20. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–1715
  21. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–1704
  22. Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996;88:1580–1586
  23. Overholt SM, Liu TJ, Taylor DL, et al. Head and neck squamous cell growth suppression using adenovirus-p53-FLAG: a potential marker for gene therapy trials. Clin Cancer Res. 1997;3:185–191
  24. Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998;16:2221–2232
  25. Tumor Nemunaitis J, Hamm J, Clayman GL, et al. Response criteria and biomarkers associated with increased survival following adenoviral p53 gene therapy (ADVEXIN) in patients with recurrent squamous cell carcinoma of the head and neck. In: Annual Meeting: Proceedings American Society of Clinical Oncology. 2007;
  26. Yoo GH, Piechocki MP, Oliver J, et al. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope. 2004;114:1871–1879
  27. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer. 1999;83:151–156
  28. Pucci B, Bellincampi L, Tafani M, et al. Paclitaxel induces apoptosis in Saos-2 cells with CD95L upregulation and Bcl-2 phosphorylation. Exp Cell Res. 1999;252:134–143
  29. Yoo GH, Subramanian G, Boinpally RR, et al. An in vivo evaluation of docetaxel delivered intratumorally in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2005;131:418–429
  30. Clayman GL, L S, Laramore GE, et al. Head and neck cancer. In:  Bast RC,  K D,  Pollock RE, et al. editor. Cancer Medicine. Hamilton: B.C. Decker Inc.; 2000;p. 1175–1220
  31. Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med. 1993;328:184–194
  32. Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 1995;22:3–16
  33. Horio Y, Hasegawa Y, Sekido Y, et al. Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells. Cancer Gene Ther. 2000;7:537–544
  34. Inoue A, Narumi K, Matsubara N, et al. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett. 2000;157:105–112
  35. Shieh SY, Ikeda M, Taya Y, et al. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91:325–334
  36. Kuerbitz SJ, Plunkett BS, Walsh WV, et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA. 1992;89:7491–7495
  37. Safran H, King T, Choy H, et al. p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. Cancer. 1996;78:1203–1210

☆ This work was supported by the National Institute of Health/National Institute of Dental and Craniofacial Research (R21 DE014878).

PII: S0196-0709(08)00232-9

doi: 10.1016/j.amjoto.2008.10.002

American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 31, Issue 2 , Pages 78-83 , March 2010

Article Tools

* Image Usage & Resolution